Recipharm Invests in BFS Technology

Article

Kaysersberg facility’s Lab+ deal expected to bolster CDMO’s filling services

Recipharm has boosted its sterile filling capabilities by investing in Lab+ technology for low volume blow-fill-seal (BFS) filling at its facility in Kaysersberg, France.

BFS is an automated manufacturing process where plastic ampoules are blow-formed, filled, and sealed in a continuous operation. The contract development and manufacturing organization (CDMO) provides sterile BFS contract manufacturing for a range of pharma products and applications including gels, solutions, suspensions, emulsions, and aseptically packed single-use vaccines.

With a throughput speed of 2,000 doses per hour and a flexible design, Lab+ is ideal for BFS projects that require smaller volumes. With a streamlined tooling changeover process, this tech is able to be adapted for a range of different product types and dosage designs. The system can also be charged with formulation using both conventional stainless-steel vessels or single-use charge bags.

“ … This new machinery means we can make small batches and removes the need to dedicate a whole filling line to one project. We can offer a system that is new, and rare on the market, allowing our customers to design and test their products, to see how they will look and react in a BFS system,” says Yves Buelens, site manager at Recipharm.

Read more about the investment here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.